Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
SAN DIEGO, Feb. 21, 2017 -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) (“TearLab” or the “Company”) will announce its fourth quarter and full-year 2016 financial results after market close on Thursday, March 9, 2017.
TearLab’s Chief Executive Officer, Seph Jensen and Chief Financial Officer, Wes Brazell, will host a conference call at 4:30 p.m. ET on the same day to review the financial results and discuss recent business developments.
Fourth Quarter 2016 Results Conference Call Details:
Date: Thursday, March 9, 2017
Time: 4:30 p.m. ET
Live Call: 877-303-1593 (Pass Code: 74547130)
Replay: 855-859-2056 (Pass Code: 74547130)
The call will also be broadcast live and archived on the Company's website at www.tearlab.com under the "Webcasts" tab in the Investor's section.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning our future financial and operational performance. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management’s current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including. but not limited to our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 9, 2016, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 9, 2016. We do not undertake to update any forward-looking statements except as required by law.
Investor Contact: The Ruth Group Lee Roth Tel: 646-536-7012 [email protected]
